Despite the multiple beneficial therapeutic effects of SGLT2 inhibitors, fresh concerns have emerged regarding their potential to elevate the risk of euglycemic diabetic ketoacidosis (euDKA), particularly in individuals with type 1 diabetes mellitus (T1DM) and latent autoimmune diabetes (LADA) [8,9]. Here, SLC5A2 is linked to latent autoimmune diabetes in adults.